Cigna is expected to report Q1 2026 revenue of $66.74 billion and adjusted EPS of $7.54, with its current stock price of $282.43 trading significantly below the average analyst target of $332.47.
Investors are primarily focused on the Medical Care Ratio (MCR), which serves as a critical indicator of medical cost management following the 2025 divestiture of its Medicare Advantage business.
The market is looking for evidence that the high-growth Evernorth segment can offset sector-wide margin pressures through its expanded specialty pharmacy and GLP-1 drug coverage offerings. Analysts are also closely monitoring pharmacy benefit management (PBM) contract renewals and the financial impact of transitioning to new rebate models.